What Is Astrocytoma?
Astrocytoma is a primary brain tumor that develops from astrocytes, the supporting cells of the brain, and accounts for roughly one third of all primary brain tumors. It can occur at any age; the well-behaved pilocytic astrocytoma predominates in children, while the diffuse astrocytomas that tend to infiltrate predominate in adults. The 2021 WHO classification redefined adult diffuse gliomas by IDH status: IDH-mutant astrocytoma is now considered a single tumor type, graded 2, 3 or 4, and carries a markedly better prognosis than IDH-wildtype glioblastoma. For this reason a diagnosis of 'astrocytoma' alone is not a treatment prescription; grade and molecular profile are decisive.
Symptoms and Diagnosis
The most common presenting complaint in astrocytoma is epileptic seizures, particularly with low-grade cortical tumors. Other features include headache from raised intracranial pressure, personality and behavioral changes, memory and concentration difficulties, speech disturbance (aphasia), and location-dependent limb weakness or incoordination. MRI is the principal diagnostic tool, showing an infiltrative, hyperintense lesion on T2 and FLAIR sequences. Advanced MRI techniques and amino-acid PET help assess tumor grade. Definitive diagnosis is made by pathological and molecular examination (IDH, ATRX, TP53, CDKN2A/B) of tissue obtained by stereotactic biopsy or surgical resection; these markers are critical for diagnosis, grading and prognosis.
The Decision Is Individualized by IDH Status and Grade
Treatment is individualized according to grade, IDH status, molecular profile, tumor location and the patient's condition. The first step is usually the widest safe surgical resection. For low-grade IDH-mutant tumors, options after surgery include close MRI surveillance, the brain-penetrant IDH inhibitor vorasidenib (approved for certain grade 2 cases after surgery), and radiotherapy with chemotherapy when needed. For higher-grade cases, radiotherapy and chemotherapy (temozolomide or PCV) are added to surgery. In the presence of microvascular proliferation, necrosis or homozygous CDKN2A/B deletion, the tumor is considered grade 4 regardless of histology and treatment is intensified. The entire decision is made by a multidisciplinary team.
The Surgical Process and Preserving Function
Because astrocytoma infiltrates the surrounding brain, the aim of surgery is the widest possible resection while preserving function; the volume of tumor removed influences survival and time to recurrence, while the function preserved determines quality of life. To strike this balance, neuronavigation, functional MRI and DTI tractography, awake craniotomy and cortical mapping when needed, and methods that help define the margin in low-grade tumors are used. During preparation a detailed neurological examination, contrast MRI and an anaesthetic assessment are carried out. After surgery there is usually 24–48 hours of intensive care and a few days in hospital; the extent of resection is assessed with a control MRI, and the next treatment is planned according to the pathological-molecular result.
Prognosis and Realistic Expectations
One of the strongest determinants of prognosis is IDH mutation status; survival in IDH-mutant astrocytomas is markedly longer than in IDH-wildtype glioblastoma and varies by grade. Because low-grade tumors may transform to higher grade over time, close MRI follow-up is important. The risks of surgery (bleeding, infection, a temporary or permanent neurological deficit, edema, seizures) are discussed openly. We do not promise a guaranteed result; each patient's course is different, treatment is delivered by a multidisciplinary team, and expectations are shared clearly before surgery.